REALITIES AND PROSPECTS FOR PHARMACOLOGICAL CORRECTION OF «ADMA-ENOS"-ASSOCIATED WAYS IN PREECLAMPSIA

• Main Authors: M. V. Pokrovsky (Author), N. G. Filipenko (Author), M. V. Korokin (Author), V. V. Gureyev (Author), T. G. Pokrovsky (Author), A. A. Barsuk (Author), L. V. Korokina (Author), E. V. Proskuryakova (Author), N. V. Maltseva (Author), O. V. Levashova (Author), O. S. Gudyrev (Author), A. S. Belous (Author), O. S. Polyanskaya (Author)
• Format: Book
• Published: Столичная издательская компания, 2016-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Methylated analogs of L-arginine - asymmetric dimetilarginin (ADMA) and monometilarginin (L-NMMA) - are endogenous inhibitors of endothelial NO-synthase (eNOS). ADMA level in maternal plasma is increased in women with preeclampsia. The high level of ADMA is one of the predictors of preeclampsia. L-arginine increases the activity of eNOS and production of nitric oxide in the ADMA-similar model of L-NAME-induced endothelial dysfunction. ENOS activator (resveratrol), antioxidants, potentiated polyclonal antibodies to eNOS and others agents have been effective in this model. Studies of endotelioprotective activity in other «ADMA-eNOS-associated" experimental models of metabolic syndrome and homocysteine-induced, gipoestrogen-induced sepsis-induced endothelial dysfunction and endothelial dysfunction in postvaccinal vasculitis have been developed.

Item Description

1819-6446
2225-3653
10.20996/1819-6446-2010-6-6-882-887